~~<i id='26F2E7BAA9'><strike id='26F2E7BAA9'><tt id='26F2E7BAA9'><pre id='26F2E7BAA9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

author：explore 2025-10-01 23:02:10 - browse：822

It’s that time of the year again when I recognize the Best Biopharma CEO of the year.

This year’s selection is so deservingly obvious that I won’t fabricate suspense by starting with an honor roll of runners-up. More on those high-achieving folks later. Let’s get right to the main course: David Ricks of Eli Lillyis the runaway, rock star, who-else-could-it-be Best Biopharma CEO of 2023.

What an incredible year it’s been for Ricks and the Lilly executive team who helped him achieve so much. My colleague Matt Herper wrote earlier this year about the “dynamic duo” of Ricks and Chief Scientific Officer Dan Skovronsky.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Designating disabled people as health disparity population is crucial

leisure time

hotspot

leisure time

hotspot

knowledge

focus

LISELOTTESABROE/Scanpix/AFPviaGettyImagesLEXINGTON,Mass.—NewobesitydrugslikeWegovyandZepboundarecurr

WSS

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Ohio train derailment: Experts on toxic chemical risks

HHS names first

Risky weight loss products often used by teens globally, per study

New Medicare drug pricing powers could soon be upended in court

Risky weight loss products often used by teens globally, per study

knowledge

knowledge

leisure time

Supreme Court strikes down use of affirmative action

CDC panel: People 65 and older should get a Covid spring booster shot

Hollywood unions extend contract negotiations for actors

Medicare Advantage isn’t working — for anyone

After affirmative action ruling, medical educators look to 'holistic review'

Medicare Advantage isn’t working — for anyone

Affirmative action in medical school literally saved lives

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

BioMarin wins approval for gene therapy to treat hemophilia A

Fauci’s Covid grilling leads GOP to weigh foreign research rules

hotspot

CDC advisory group OKs chikungunya vaccine

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Change Healthcare cyberattack shows risk of industry consolidation

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Generative AI mines health records to identify patients’ social needs

leisure time

hotspot

knowledge

focus